Celldex Therapeutics (CLDX) | Stock Overview & Key Data
Celldex Therapeutics Performance Comparison
Stock Range
Today's Range
Low: $21.56
High: $22.75
on August 22, 2025
52 Week Range
Low: $14.40
High: $47.00
on April 9, 2025
on September 25, 2024
All-Time High: $3,375.00 on March 6, 2000
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.5B
EPS
-3.01
P/E Ratio (TTM)
-9.17
Forward P/E
-6.82
P/B Ratio
2.23
PEG Ratio
-0.16
Div. Yield
N/A
ROE
-27.18%
Beta
1.223
Debt to Equity
0.46
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-8,747.53%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-19.08%
Return on Equity (TTM)
-27.18%
EBITDA
$-231.4M
Net Income (TTM)
$-199.6M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$0.09
Quarterly Revenue Growth (YoY)
-70.80%
Quarterly Earnings Growth (YoY)
-70.78%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Celldex Therapeutics CLDX | 1.46B Small-cap | -11.92% | 0.45% | 10.26% | 5.30% | -12.91% | -39.57% | -28.68% | 87.17% |
| Vertex VRTX | 101.31B Large-cap | 0.59% | -15.96% | -8.96% | -17.97% | -2.62% | -17.90% | 40.27% | 46.36% |
| Regeneron REGN | 63.57B Large-cap | 1.56% | 5.09% | -1.23% | -17.35% | -17.58% | -50.84% | -1.12% | -2.18% |
| Sarepta Therapeutics SRPT | 1.98B Small-cap | -7.29% | 48.46% | -47.87% | -80.85% | -83.71% | -85.61% | -81.93% | -86.29% |
| Adaptive ADPT | 1.92B Small-cap | -0.31% | 23.46% | 47.06% | 54.39% | 110.02% | 167.49% | 24.05% | -68.15% |
| Arcutis ARQT | 1.92B Small-cap | -5.39% | 9.83% | 16.98% | 28.97% | 9.75% | 62.56% | -34.67% | -35.04% |
Ownership & Short Interest
Insider Ownership
0.19%
Institutional Ownership
111.59%
Shares Short
8M
Short Ratio
8.06
Short % of Shares Outstanding
13.85%
Average 10-Day Volume
2M
Average 90-Day Volume
1M
Celldex Therapeutics Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Celldex Therapeutics would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is CLDX's 52-week high and low?
- In the last 52 weeks, Celldex Therapeutics reached a high of $47.00 (on September 25, 2024) and a low of $14.40 (on April 9, 2025).
- What is the market cap and P/E ratio for CLDX?
- Curious about Celldex Therapeutics's size and valuation? Its market capitalization stands at 1.46B. When it comes to valuation, the P/E ratio (trailing twelve months) is -9.17, and the forward P/E (looking ahead) is -6.82.
- Does CLDX pay dividends? If so, what's the yield?
- As for dividends, Celldex Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Celldex Therapeutics's main competitors or similar companies to consider before investing?
When looking at Celldex Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX101.31B Healthcare Biotechnology -17.90% 40.27% Regeneron
REGN63.57B Healthcare Biotechnology -50.84% -1.12% Sarepta Therapeutics
SRPT1.98B Healthcare Biotechnology -85.61% -81.93% Adaptive
ADPT1.92B Healthcare Biotechnology 167.49% 24.05% Arcutis
ARQT1.92B Healthcare Biotechnology 62.56% -34.67% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Celldex Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Celldex Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -27.18%, the Debt to Equity ratio from the most recent quarter is 0.46, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for CLDX?
- Looking at Celldex Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $6M. Compared to the same quarter last year (YoY), quarterly revenue grew by -70.80%, and quarterly earnings saw a YoY growth of -70.78%.
- How much of CLDX stock is held by insiders and institutions?
- Wondering who owns Celldex Therapeutics stock? Company insiders (like executives and directors) hold about 0.19% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 111.59%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.